Goldman Sachs Maintains Buy on IDEXX Laboratories, Lowers Price Target to $500
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich has maintained a 'Buy' rating on IDEXX Laboratories (NASDAQ:IDXX), but lowered the price target from $578 to $500.
November 03, 2023 | 2:42 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on IDEXX Laboratories, but lowered the price target from $578 to $500.
The news is directly related to IDEXX Laboratories. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100